Cargando…

The breast tissue microbiome, stroma, immune cells and breast cancer

BACKGROUND: Stromal and immune cell composition alterations in benign breast tissue associate with future cancer risk. Pilot data suggest the innate microbiome of normal breast tissue differs between women with and without breast cancer. Microbiome alterations might explain tissue microenvironment v...

Descripción completa

Detalles Bibliográficos
Autores principales: Hieken, Tina J, Chen, Jun, Chen, Beiyun, Johnson, Stephen, Hoskin, Tanya L, Degnim, Amy C, Walther-Antonio, Marina R, Chia, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971327/
https://www.ncbi.nlm.nih.gov/pubmed/35366464
http://dx.doi.org/10.1016/j.neo.2022.100786
_version_ 1784679608449236992
author Hieken, Tina J
Chen, Jun
Chen, Beiyun
Johnson, Stephen
Hoskin, Tanya L
Degnim, Amy C
Walther-Antonio, Marina R
Chia, Nicholas
author_facet Hieken, Tina J
Chen, Jun
Chen, Beiyun
Johnson, Stephen
Hoskin, Tanya L
Degnim, Amy C
Walther-Antonio, Marina R
Chia, Nicholas
author_sort Hieken, Tina J
collection PubMed
description BACKGROUND: Stromal and immune cell composition alterations in benign breast tissue associate with future cancer risk. Pilot data suggest the innate microbiome of normal breast tissue differs between women with and without breast cancer. Microbiome alterations might explain tissue microenvironment variations associated with disease status. METHODS: Prospectively-collected sterile normal breast tissues from women with benign (n=16) or malignant (n=17) disease underwent 16SrRNA sequencing with Illumina MiSeq and Hybrid-denovo pipeline processing. Breast tissue was scored for fibrosis and fat percentages and immune cell infiltrates (lobulitis) classified as absent/mild/moderate/severe. Alpha and beta diversity were calculated on rarefied OTU data and associations analyzed with multiple linear regression and PERMANOVA. RESULTS: Breast tissue stromal fat% was lower and fibrosis% higher in benign disease versus cancer (median 30% versus 60%, p=0.01, 70% versus 30%, p=0.002, respectively). The microbiome varied with stromal composition. Alpha diversity (Chao1) correlated with fat% (r=0.38, p=0.02) and fibrosis% (r=-0.32, p=0.05) and associated with different microbial populations as indicated by beta diversity metrics (weighted UniFrac, p=0.08, fat%, p=0.07, fibrosis%). Permutation testing with FDR control revealed taxa differences for fat% in Firmicutes, Bacilli, Bacillales, Staphylococcaceae and genus Staphylococcus, and fibrosis% in Firmicutes, Spirochaetes, Bacilli, Bacillales, Spirochaetales, Proteobacteria RF32, Sphingomonadales, Staphylococcaceae, and genera Clostridium, Staphylococcus, Spirochaetes, Actinobacteria Adlercreutzia. Moderate/severe lobulitis was more common in cancer (73%) than benign disease (13%), p=0.003, but no significant microbial associations were seen. CONCLUSION: These data suggest a link between breast tissue stromal alterations and its microbiome, further supporting a connection between the breast tissue microenvironment and breast cancer.
format Online
Article
Text
id pubmed-8971327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-89713272022-04-07 The breast tissue microbiome, stroma, immune cells and breast cancer Hieken, Tina J Chen, Jun Chen, Beiyun Johnson, Stephen Hoskin, Tanya L Degnim, Amy C Walther-Antonio, Marina R Chia, Nicholas Neoplasia Original article BACKGROUND: Stromal and immune cell composition alterations in benign breast tissue associate with future cancer risk. Pilot data suggest the innate microbiome of normal breast tissue differs between women with and without breast cancer. Microbiome alterations might explain tissue microenvironment variations associated with disease status. METHODS: Prospectively-collected sterile normal breast tissues from women with benign (n=16) or malignant (n=17) disease underwent 16SrRNA sequencing with Illumina MiSeq and Hybrid-denovo pipeline processing. Breast tissue was scored for fibrosis and fat percentages and immune cell infiltrates (lobulitis) classified as absent/mild/moderate/severe. Alpha and beta diversity were calculated on rarefied OTU data and associations analyzed with multiple linear regression and PERMANOVA. RESULTS: Breast tissue stromal fat% was lower and fibrosis% higher in benign disease versus cancer (median 30% versus 60%, p=0.01, 70% versus 30%, p=0.002, respectively). The microbiome varied with stromal composition. Alpha diversity (Chao1) correlated with fat% (r=0.38, p=0.02) and fibrosis% (r=-0.32, p=0.05) and associated with different microbial populations as indicated by beta diversity metrics (weighted UniFrac, p=0.08, fat%, p=0.07, fibrosis%). Permutation testing with FDR control revealed taxa differences for fat% in Firmicutes, Bacilli, Bacillales, Staphylococcaceae and genus Staphylococcus, and fibrosis% in Firmicutes, Spirochaetes, Bacilli, Bacillales, Spirochaetales, Proteobacteria RF32, Sphingomonadales, Staphylococcaceae, and genera Clostridium, Staphylococcus, Spirochaetes, Actinobacteria Adlercreutzia. Moderate/severe lobulitis was more common in cancer (73%) than benign disease (13%), p=0.003, but no significant microbial associations were seen. CONCLUSION: These data suggest a link between breast tissue stromal alterations and its microbiome, further supporting a connection between the breast tissue microenvironment and breast cancer. Neoplasia Press 2022-03-30 /pmc/articles/PMC8971327/ /pubmed/35366464 http://dx.doi.org/10.1016/j.neo.2022.100786 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Hieken, Tina J
Chen, Jun
Chen, Beiyun
Johnson, Stephen
Hoskin, Tanya L
Degnim, Amy C
Walther-Antonio, Marina R
Chia, Nicholas
The breast tissue microbiome, stroma, immune cells and breast cancer
title The breast tissue microbiome, stroma, immune cells and breast cancer
title_full The breast tissue microbiome, stroma, immune cells and breast cancer
title_fullStr The breast tissue microbiome, stroma, immune cells and breast cancer
title_full_unstemmed The breast tissue microbiome, stroma, immune cells and breast cancer
title_short The breast tissue microbiome, stroma, immune cells and breast cancer
title_sort breast tissue microbiome, stroma, immune cells and breast cancer
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971327/
https://www.ncbi.nlm.nih.gov/pubmed/35366464
http://dx.doi.org/10.1016/j.neo.2022.100786
work_keys_str_mv AT hiekentinaj thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chenjun thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chenbeiyun thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT johnsonstephen thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT hoskintanyal thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT degnimamyc thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT waltherantoniomarinar thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chianicholas thebreasttissuemicrobiomestromaimmunecellsandbreastcancer
AT hiekentinaj breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chenjun breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chenbeiyun breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT johnsonstephen breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT hoskintanyal breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT degnimamyc breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT waltherantoniomarinar breasttissuemicrobiomestromaimmunecellsandbreastcancer
AT chianicholas breasttissuemicrobiomestromaimmunecellsandbreastcancer